Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is primarily driven by the Bcr-Abl oncoprotein.
• The SKP2/Bcr-Abl pathway plays a crucial role in CML pathogenesis and progression.
• Targeting this pathway presents a promising therapeutic strategy for CML.

Purpose of the Study:

• To identify novel inhibitors of the SKP2/Bcr-Abl pathway from natural products.
• To evaluate the therapeutic potential of identified compounds in CML models.

Main Methods:

• Large-scale screening of natural products to identify SKP2/Bcr-Abl pathway inhibitors.
• In vitro assays to assess the effect of compounds on CML cell lines.
• In vivo studies using CML xenograft models to evaluate anti-tumor activity.

Main Results:

• Diosmetin, a phytoestrogen, was identified as a potent inhibitor of the SKP2/Bcr-Abl pathway.
• Diosmetin significantly downregulated SKP2 expression and Bcr-Abl phosphorylation.
• Diosmetin demonstrated favorable anti-tumor activity in CML cells and xenograft models.

Conclusions:

• Diosmetin is a natural compound with significant anti-CML activity.
• Diosmetin exerts its effects by targeting the SKP2/Bcr-Abl signaling pathway.
• Diosmetin represents a potential novel therapeutic agent for CML treatment.